Table 1.

2016 revenue and losses for four publicly traded, genomic-testing companies ($ in millions)

	Myriad	Invitate	Natera	CombiMatrix
Revenuea	$753.8	$25.1	$217.1	$12.9
Expenses
Cost of revenueb	$157.3	$27.9	$135.6	$5.8
Research and development	$70.6	$44.6	$41.9	$0.5
Selling and marketing	$359.1	$28.6	$136.1	$4.6
General and administrative	Merged with selling and marketing	$24.1	Merged with selling and marketing	$6.0
Total expenses	$429.7	$125.2	$313.6	$17.0
Operating income (loss)c	$166.8	($100.2)	($96.5)	($4.1)
Net income (loss)d	$125.3	($100.3)	($95.1)	($4.1)

Source for these numbers are from the companies’ SEC 10-K filings

^aRevenue from testing, licensing, pharmaceutical services, and other sources

^bThe costs for receiving test samples, performing tests, reporting test results, and other activities directly related to an individual test

^cObtaining by subtracting “total expenses” from “revenue”

^d“Operating income” plus other income (expenses), taxes, and interest expense